Sabby Management’s Epizyme, Inc EPZM Stock Holding History

Sabby Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-111,536	Closed	-$2.1M	–	374
2015 Q1	$2.1M	Buy	+111,536	New	+$2.3M	0.09%	142
2014 Q3	–	Sell	-48,790	Closed	-$1.52M	–	311
2014 Q2	$1.52M	Sell	48,790 -102,430	-68%	-$2.41M	0.07%	122
2014 Q1	$3.44M	Buy	+151,220	New	+$4.58M	0.19%	78

Other funds holding EPZM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Sabby Management's EPZM Position: Q2 2015 in Review

Sabby Management sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 111,536 shares — an estimated $2.1M sold.

Sabby Management first reported a position in EPZM in Q1 2014 and held it in 3 quarters. The position peaked at $3.44M in Q1 2014. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

Sabby Management reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
Sabby Management sold 111,536 Epizyme, Inc shares in Q2 2015, an estimated $2.1M.
Sabby Management first reported a position in Epizyme, Inc in Q1 2014 and held it in 3 quarters.
Sabby Management's Epizyme, Inc position peaked at $3.44M in Q1 2014.
95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.